The effect of Ivacaftor in CF patients with a class III mutatio

Phase 4

Completed

• Conditions: Cystic Fibrosis; Mucoviscidosis; 10038686

• Registration Number: NL-OMON41740
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2015-08-28
• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 16

Inclusion Criteria

• CFTR genotype associated with residual CFTR function;
• Already had a rectal biopsy to produce an organoid;
• Start a treatment with Ivacaftor;
• Male and female patients, aged 6 years or older on the date of informed consent;
• Signed informed consent form (IC), and where appropriate, signed assent form.

Exclusion Criteria

• Use of curcumin and or genistein at start or within two weeks prior to start of the study;
• Inability to follow instructions of the investigator.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Sweat chloride concentration before and after receiving Ivacaftor.</p><br>